Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 161

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Prolonged Low-Dose Methylprednisolone in Patients With Severe COVID-19 Pneumonia

Open access
Salton, Francesco, Confalonieri, Paola, Meduri, G Umberto, Santus, Pierachille, Harari, Sergio, Scala, Raffaele, Lanini, Simone, Vertui, Valentina, Oggionni, Tiberio, Caminati, Antonella, Patruno, Vincenzo, Tamburrini, Mario, Scartabellati, Alessandro, Parati, Mara, Villani, Massimiliano, Radovanovic, Dejan, Tomassetti, Sara, Ravaglia, Claudia, Poletti, Venerino, Vianello, Andrea, Gaccione, Anna Talia, Guidelli, Luca, Raccanelli, Rita, Lucernoni, Paolo, Lacedonia, Donato, Foschino Barbaro, Maria Pia, Centanni, Stefano, Mondoni, Michele, Davì, Matteo, Fantin, Alberto, Cao, Xueyuan, Torelli, Lucio, Zucchetto, Antonella, Montico, Marcella, Casarin, Annalisa, Romagnoli, Micaela, Gasparini, Stefano, Bonifazi, Martina, D’Agaro, Pierlanfranco, Marcello, Alessandro, Licastro, Danilo, Ruaro, Barbara, Volpe, Maria Concetta, Umberger, Reba, Confalonieri, Marco·2020·Open Forum Infectious Diseases

Abstract

Background: In hospitalized patients with coronavirus disease 2019 (COVID-19) pneumonia, progression to acute respiratory failure requiring invasive mechanical ventilation (MV) is associated with significant morbidity and mortality. Severe dysregulated systemic inflammation is the putative mechanism. We hypothesize that early prolonged methylprednisolone (MP) treatment could accelerate disease resolution, decreasing the need for intensive care unit (ICU) admission and mortality. Methods: We conducted a multicenter observational study to explore the association between exposure to prolonged, low-dose MP treatment and need for ICU referral, intubation, or death within 28 days (composite primary end point) in patients with severe COVID-19 pneumonia admitted to Italian respiratory high-dependency units. Secondary outcomes were invasive MV-free days and changes in C-reactive protein (CRP) levels. Results: Findings are reported as MP (n = 83) vs control (n = 90). The composite primary end point was met by 19 vs 40 (adjusted hazard ratio [aHR], 0.41; 95% CI, 0.24–0.72). Transfer to ICU and invasive MV were necessary in 15 vs 27 (P = .07) and 14 vs 26 (P = .10), respectively. By day 28, the MP group had fewer deaths (6 vs 21; aHR, 0.29; 95% CI, 0.12–0.73) and more days off invasive MV (24.0 ± 9.0 vs 17.5 ± 12.8; P = .001). Study treatment was associated with rapid improvement in PaO2:FiO2 and CRP levels. The complication rate was similar for the 2 groups (P = .84). Conclusion: In patients with severe COVID-19 pneumonia, early administration of prolonged, low dose MP treatment was associated with a significantly lower hazard of death (71%) and decreased ventilator dependence. Treatment was safe and did not impact viral clearance. A large randomized controlled trial (RECOVERY trial) has been performed that validates these findings. Clinical trial registration. ClinicalTrials.gov NCT04323592.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/ofid/ofaa421

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

Metadata

Authors
Salton, F., Confalonieri, P., Meduri, G. U., Santus, P., Harari, S., Scala, R., Lanini, S., Vertui, V., Oggionni, T., Caminati, A., Patruno, V., Tamburrini, M., Scartabellati, A., Parati, M., Villani, M., Radovanovic, D., Tomassetti, S., Ravaglia, C., Poletti, V., Vianello, A., Gaccione, A. T., Guidelli, L., Raccanelli, R., Lucernoni, P., Lacedonia, D., Foschino Barbaro, M. P., Centanni, S., Mondoni, M., Davì, M., Fantin, A., Cao, X., Torelli, L., Zucchetto, A., Montico, M., Casarin, A., Romagnoli, M., Gasparini, S., Bonifazi, M., D’Agaro, P., Marcello, A., Licastro, D., Ruaro, B., Volpe, M. C., Umberger, R., & Confalonieri, M.
Venue
Open Forum Infectious Diseases
Published
2020-09-12
Volume
7
Issue
10
Pages
ofaa421-ofaa421
ISSN
2328-8957 (ISSN-L)
OpenAlex
W3085008014
Cited by
161
References
7
FWCI
4.35
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.